🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 829399104 (prev. G0750W203 )
- Market Cap
- Small Cap · $105 Million
- IPO
- 6/10/2015 · $15.00/share
- Previous Symbol
- AXGT (changed 11/13/2020)
- Previous Name
- Axovant Gene Therapies Ltd.
Business: Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease.
Notes: May 07, 2019 -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that a reverse share split of its common shares on a 1-for-8 basis will become effective on May 7, 2019. The shares will begin trading on the split-adjusted basis on the Nasdaq Global Select Market under the Company's existing trading symbol "AXGT" on May 8, 2019. The new CUSIP number following the reverse share split will be G0750W203.
Company Contact
- CEO
- Pavan Cheruvu
- CFO
- David Nassif
- Headquarters
- 11 Times Square, 33rd Floor, New York, NY
- Phone
- 877-746-4891 · Toll-Free 877-746-4891
- Investor Relations
- David Nassif · 646-677-6770 · investors@siogtx.com